Tandem Diabetes Care, Inc. TNDM R2KR3KPHARMA
Company Overview
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Why Investors Should Care
Revenue has grown at a 58.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $1.01B (+7.9% YoY); net profit $-204.71M.
- Trailing 12 Months Year-on-year growth — revenue +5.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 58.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 58.85% |
| 1 Year: | 5.50% |
Stock Price Performance
| 1 Year: | +78.80% |
| 6 Months: | -5.87% |
| 3 Months: | +2.90% |
| 1 Month: | +5.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)42.66 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 58.9% over 5 years.
CONS
- Trading 29.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TNDM Tandem Diabetes Care, Inc. R2KR3KPHARMA | 19.90 | -12.21 | $1.38B | 0.00% | -29.33% | -65.73% | 58.85% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 18.98M | 21.33M | 27.00M | 40.29M | 27.28M | 34.13M | 46.26M | 76.20M | 66.00M | 93.25M | 94.66M | 108.40M | 97.93M | 109.24M | 123.60M | 168.06M | 141.04M | 172.14M | 179.63M | 210.00M | 175.91M | 200.26M | 204.55M | 220.50M | 169.38M | 195.92M | 185.62M | 196.80M | 191.67M | 221.91M | 243.97M | 282.65M | 234.42M | 240.68M | 249.25M | 290.38M | 247.22M | 254.56M |
| Gross Profit | -1.58M | 10.06M | 6.75M | 8.00M | 11.87M | 17.47M | 11.40M | 15.09M | 21.80M | 41.53M | 33.35M | 49.90M | 50.68M | 60.27M | 50.26M | 54.39M | 65.31M | 90.56M | 73.29M | 92.45M | 96.75M | 113.73M | 91.09M | 101.95M | 104.42M | 115.52M | 82.91M | 101.73M | 89.75M | 93.30M | 94.67M | 112.79M | 124.65M | 157.46M | 118.41M | 125.86M | 134.29M | 167.46M | 136.79M | 144.78M |
| Operating Income | -28.41M | -13.35M | -21.23M | -18.97M | -13.17M | -9.58M | -15.48M | -14.00M | -15.71M | 560.00K | -11.00M | -1.86M | -6.00M | 2.14M | -13.57M | -12.04M | -1.01M | 18.66M | -3.24M | 5.43M | 7.72M | 12.74M | -15.34M | -12.24M | -47.49M | -17.78M | -127.82M | -38.81M | -31.55M | -35.06M | -41.68M | -30.77M | -26.09M | -581.00K | -120.88M | -51.81M | -22.86M | 8.29M | -17.43M | -13.79M |
| Net Income | -29.82M | -14.82M | -23.79M | -21.80M | -16.03M | -11.41M | -32.69M | -59.36M | -34.24M | 3.69M | -22.99M | -1.51M | -2.90M | 2.65M | -14.87M | -27.11M | -9.41M | 17.00M | -5.04M | 4.01M | 5.79M | 10.81M | -14.71M | -15.06M | -48.97M | -15.85M | -123.87M | -35.77M | -32.96M | -30.00M | -42.72M | -30.81M | -23.25M | 755.00K | -130.56M | -52.40M | -21.16M | -589.00K | -20.39M | -21.17M |
| Diluted EPS | - | - | - | - | - | - | -1.82 | -1.17 | -0.62 | 0.02 | -0.40 | -0.03 | -0.09 | 0.04 | -0.25 | -0.45 | -0.15 | 0.22 | -0.08 | 0.06 | 0.09 | 0.16 | -0.23 | -0.24 | -0.76 | -0.25 | -1.92 | -0.55 | -0.51 | -0.46 | -0.65 | -0.47 | -0.35 | 0.01 | -1.97 | -0.78 | -0.31 | -0.01 | -0.30 | -0.31 |
| R&D Expense | 6.15M | - | 5.13M | 4.87M | 4.91M | - | 5.97M | 6.46M | 8.00M | - | 9.39M | 11.20M | 12.04M | - | 14.12M | 15.99M | 16.09M | - | 17.96M | 20.50M | 24.10M | - | 33.16M | 33.57M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.48M | 29.01M | 49.72M | 72.85M | 84.25M | 107.60M | 183.87M | 362.31M | 498.83M | 702.80M | 801.22M | 747.72M | 940.20M | 1.01B |
| Gross Profit | -1.35M | 6.17M | 15.25M | 26.58M | 23.59M | 44.09M | 89.82M | 194.21M | 260.52M | 376.21M | 412.99M | 367.69M | 489.57M | 546.01M |
| Operating Income | -33.05M | -49.43M | -75.66M | -69.00M | -78.05M | -62.94M | -44.63M | -16.72M | -7.96M | 22.65M | -92.85M | -233.23M | -99.13M | -187.26M |
| Net Income | -33.02M | -63.14M | -79.52M | -72.42M | -83.45M | -73.03M | -122.61M | -24.75M | -34.38M | 15.57M | -94.59M | -222.61M | -96.03M | -204.71M |
| Diluted EPS | - | - | - | - | - | - | - | -0.42 | -0.56 | 0.24 | -1.47 | -3.43 | -1.47 | -3.04 |
| R&D Expense | 9.01M | 11.08M | 15.79M | 16.96M | 18.81M | 20.66M | 29.23M | 45.20M | 63.57M | 92.05M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 162.22M | 106.46M | 124.72M | 112.39M | 95.35M | 206.29M | 326.11M | 716.41M | 905.14M | 1.05B | 952.66M | 967.66M | 881.11M |
| Total Equity | -71.30M | -106.05M | 115.54M | 54.57M | 63.47M | -5.93M | -29.15M | 131.28M | 194.98M | 366.31M | 433.11M | 439.95M | 313.63M | 263.10M | 155.17M |
| Cash & Equivalents | 8.66M | 17.16M | 124.39M | 31.18M | 43.09M | 44.68M | 13.70M | 41.83M | 51.17M | 94.61M | 71.18M | 172.52M | 58.87M | 69.23M | 90.63M |
| Long Term Debt | - | - | - | 30.00M | 30.15M | 81.08M | 82.74M | - | - | - | - | - | 285.04M | 308.27M | 310.04M |
| Total Liabilities | - | - | 46.68M | 51.89M | 61.26M | 118.32M | 124.49M | 75.02M | 131.13M | 350.11M | 472.02M | 612.84M | 639.03M | 704.56M | 725.94M |
| Current Liabilities | - | - | 14.60M | 18.09M | 26.52M | 31.48M | 36.09M | 66.29M | 99.40M | 103.85M | 131.86M | 165.29M | 195.26M | 247.05M | 242.72M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -61.17M | -66.14M | -8.32M | 41.91M | 24.67M | - | 50.46M | -31.81M | 24.23M | -9.72M |
| Investing Cash Flow | - | - | - | - | 10.45M | 2.78M | -90.74M | -56.95M | -296.06M | - | 33.17M | -85.74M | -23.48M | 72.88M |
| Financing Cash Flow | - | - | - | - | 52.31M | 40.38M | 117.18M | 24.21M | 314.44M | - | 16.88M | 4.11M | 8.37M | -43.37M |
| Capital Expenditure | -4.53M | -4.01M | -4.41M | -5.76M | -8.93M | -5.72M | -2.99M | -19.54M | -27.41M | - | -34.10M | -96.30M | -19.23M | -98.54M |
| Free Cash Flow | - | - | - | - | -70.10M | -71.85M | -11.30M | 22.36M | -2.74M | - | 16.37M | -128.11M | 4.99M | -108.26M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | 100.51M | -113.44M | 9.11M | 19.79M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 30.00M | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -54.5% | 21.3% | 30.7% | 36.5% | 28.0% | 41.0% | 48.9% | 53.6% | 52.2% | 53.5% | 51.5% | 49.2% | 52.1% | 53.8% |
| Operating Margin % | -1,335.3% | -170.4% | -152.2% | -94.7% | -92.6% | -58.5% | -24.3% | -4.6% | -1.6% | 3.2% | -11.6% | -31.2% | -10.5% | -18.5% |
| Net Margin % | -1,333.9% | -217.7% | -159.9% | -99.4% | -99.0% | -67.9% | -66.7% | -6.8% | -6.9% | 2.2% | -11.8% | -29.8% | -10.2% | -20.2% |
| ROE % | 31.1% | -54.6% | -145.7% | -114.1% | 1,407.9% | 250.6% | -93.4% | -12.7% | -9.4% | 3.6% | -21.5% | -71.0% | -36.5% | -131.9% |
| ROCE % | - | -33.5% | -85.6% | -70.3% | -96.5% | -106.2% | -31.9% | -7.4% | -1.3% | 2.9% | -10.5% | -30.8% | -13.8% | -29.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 16.65% | 11.58M | $248.23M |
| 2 | Sessa Capital IM, L.P. | 7.33% | 5.10M | $109.29M |
| 3 | Vanguard Portfolio Management LLC | 6.18% | 4.30M | $92.14M |
| 4 | First Light Asset Management, LLC | 4.86% | 3.38M | $72.51M |
| 5 | Vanguard Capital Management LLC | 4.45% | 3.10M | $66.36M |
| 6 | State Street Corporation | 4.10% | 2.85M | $61.11M |
| 7 | GW&K Investment Management, LLC | 3.69% | 2.57M | $55.05M |
| 8 | Jennison Associates LLC | 3.35% | 2.33M | $49.96M |
| 9 | Paradice Investment Management, LLC | 2.91% | 2.02M | $43.37M |
| 10 | Jacobs Levy Equity Management, Inc. | 2.88% | 2.01M | $43.00M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TNDM
Why Did TNDM Stock Jump 5% After Hours Despite Q4 Earnings Miss? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPQWJnSnVzam5lMi1tdm81SDZkMl9oWGtKTEVNQVNZRzNuTjdHSGxaZ1lFZXd0c0hjS3ZqdzI2Qmd0VENqaldoYlVHdV9MOHFDZzd3cEktaFBVSlNHS2otRVRxbHQ4eVlocTZmYlNscjFOMDNIdU1KTl9FbFBVZFJLbTJDQldMenlBbHlUT2…
Why Tandem Diabetes (TNDM) Stock Is Trading Up Today - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNMmRPejFPZWRpZ2FkZ3NDSGhMWUJ2X1JWU2U1Wi0zODgzMV9SVlh1TG1fR1dkam9YakZuaWY5bTlweFhjRExGR3RkeHN2SHlZWHdCaWpodC15T1FrOGV4MnpzSzdUdGVmZXd4YVJZbU4zdlVVVS1lalpzc3VUbDNDSEJjaVRyQ3BrSU1ZT1…
Why Is Tandem Diabetes (TNDM) Stock Soaring Today - StockStory
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOcFYtclY1a1F6eGZpcVQzb2Vac29PUWcxS1RHeHN3d3FoZ0xqckpSYjBjYWJFYm5WbndmbllmVmF0VFZZVGFlLVY5NXVpQk9UUjExOGIxdFRiakl5ZW9feDh3THZjQzliTXh1RjBvd2NLRUdqU0hOWDZvV1o5T01VNDY3bzFBOE5MT0duVz…
TANDEM DIABETES CARE INC (TNDM) Stock Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE1JYXNERW8wUEIwS1BmRW5HbWxPV2F2TzVrVDJ5UmFnQXdTRWw4T01MdXF1anNRZGVjZURpMVAwUklDVGdCakxzSUJYendrcHR5QXdiMjN2RmJyaDY4c1YweFNnLVQ?oc=5" target="_blank">TANDEM DIABETES CARE INC (TNDM) …
(TNDM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNS09OQnZnZmdHR1pNNUdZS05rSEN5S3JBVkZ0S2tQalhOaVl3b3FpNDRKQXJlQ1hkTGt3VnNtUDB3U3VJYWRDdGlqUmdZcTdrU29yQThyMFpLbjdHZUY4S2w1Z1FpLWU5Q19SZDJYUElja2NxOEJlOVduZ0FxZDJPVjZwQ3lPNXNYQVJwYW…
A Look at Tandem Diabetes Care Inc (TNDM) After 3.4% Decline -- GF Value $24.05 vs Price $20.56 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTG9HVm53UXQwTG0yeEYyc3VTRHRPM0tWZVF5SmYyYU4zUm9YT1V5cUJ4cXA3M1VzS1hIVFFZTExtVThtSy0wSGRqdk1DckxvdWlRV3hyamw4aTM0djlCSXBELWw0NFZnR2xaazA2blZSREpRN2FleWRNNVUtY01WZnR5YmtUMW0xMlgtNj…
TNDM — Frequently Asked Questions
What is the current share price of Tandem Diabetes Care, Inc. (TNDM)?
As of 2026-09-07 16:24 PDT, Tandem Diabetes Care, Inc. (TNDM) trades at $19.90 on NasdaqGM. Its 52-week range is $10.66 to $28.26.
What is the market capitalisation of TNDM?
Tandem Diabetes Care, Inc. (TNDM) has a market capitalisation of $1.38B on NasdaqGM.
What is the P/E ratio of TNDM?
TNDM trades at a trailing price-to-earnings (P/E) ratio of -12.21. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 11.58.
What is the return on equity (ROE) of TNDM?
TNDM has a return on equity (ROE) of -65.73%. Its return on capital employed (ROCE) is -29.33%.
Is TNDM a good stock to buy?
This page provides a data-driven analysis of Tandem Diabetes Care, Inc. (TNDM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.